JP2010512730A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010512730A5 JP2010512730A5 JP2009524832A JP2009524832A JP2010512730A5 JP 2010512730 A5 JP2010512730 A5 JP 2010512730A5 JP 2009524832 A JP2009524832 A JP 2009524832A JP 2009524832 A JP2009524832 A JP 2009524832A JP 2010512730 A5 JP2010512730 A5 JP 2010512730A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- egfr
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 141
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 141
- 229920001184 polypeptide Polymers 0.000 claims description 137
- 150000001413 amino acids Chemical group 0.000 claims description 86
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 78
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 61
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 50
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 50
- 230000004071 biological effect Effects 0.000 claims description 28
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 23
- 208000020816 lung neoplasm Diseases 0.000 claims description 23
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 125000000539 amino acid group Chemical group 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 20
- 108020004705 Codon Proteins 0.000 claims description 18
- 235000001014 amino acid Nutrition 0.000 claims description 18
- 230000000694 effects Effects 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 17
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 17
- 230000026731 phosphorylation Effects 0.000 claims description 16
- 238000006366 phosphorylation reaction Methods 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 108091000080 Phosphotransferase Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000020233 phosphotransferase Human genes 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000012634 fragment Substances 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 235000018417 cysteine Nutrition 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 5
- 206010027476 Metastases Diseases 0.000 claims description 4
- 108091028664 Ribonucleotide Proteins 0.000 claims description 4
- 230000000692 anti-sense effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000002336 ribonucleotide Substances 0.000 claims description 4
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 238000010837 poor prognosis Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011230 binding agent Substances 0.000 description 6
- 230000008827 biological function Effects 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 2
- 108010011110 polyarginine Proteins 0.000 description 2
- UKVZSPHYQJNTOU-GQJPYGCMSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-GQJPYGCMSA-N 0.000 description 1
- 108010062307 AAVALLPAVLLALLAP Proteins 0.000 description 1
- 101800002011 Amphipathic peptide Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 108010061875 HN-1 peptide Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 description 1
- 108010088535 Pep-1 peptide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 108010025307 buforin II Proteins 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87479106P | 2006-12-13 | 2006-12-13 | |
| PCT/JP2007/074359 WO2008072777A2 (en) | 2006-12-13 | 2007-12-12 | Ttk as tumor marker and therapeutic target for lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010512730A JP2010512730A (ja) | 2010-04-30 |
| JP2010512730A5 true JP2010512730A5 (enExample) | 2012-01-19 |
Family
ID=39332098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524832A Withdrawn JP2010512730A (ja) | 2006-12-13 | 2007-12-12 | 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100009920A1 (enExample) |
| EP (3) | EP2468886A1 (enExample) |
| JP (1) | JP2010512730A (enExample) |
| TW (1) | TW200831673A (enExample) |
| WO (1) | WO2008072777A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2325306T3 (pl) * | 2005-02-25 | 2014-07-31 | Oncotherapy Science Inc | Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| ES2339524B1 (es) * | 2008-08-28 | 2011-03-22 | Proyecto De Biomedicina Cima, S.L. | Nuevo biomarcador como diana terapeutica en cancer de pulmon. |
| TW201102081A (en) | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| EP2343294A1 (en) | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
| US20120021432A1 (en) * | 2010-04-16 | 2012-01-26 | Arqule, Inc. | Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same |
| DK2630259T3 (en) * | 2010-10-20 | 2015-07-06 | Univ Bordeaux | SIGNATURES OF CLINICAL OUTCOME In gastrointestinal stromal tumors AND METHOD FOR THE TREATMENT OF gastrointestinal stromal tumors |
| KR101232084B1 (ko) * | 2011-10-31 | 2013-02-08 | 연세대학교 산학협력단 | 암 세포 바이오 마커를 동정하는 방법 및 상기 방법으로 동정한 ｎｍｄ-무관 암 세포 바이오 마커 |
| HK1217898A1 (zh) | 2013-02-22 | 2017-01-27 | 纽约市哥伦比亚大学理事会 | 通過抑制轉錄因子atf5來抑制腫瘤細胞的組合物和方法 |
| US10316077B2 (en) | 2017-02-20 | 2019-06-11 | Sapience Therapeutics, Inc. | Cell-penetrating ATF5 polypeptides and uses thereof |
| CN109423517B (zh) * | 2017-08-28 | 2022-08-05 | 中国医学科学院肿瘤医院 | 外泌体在肿瘤诊断、治疗和预后评估中的用途 |
| AU2019205351B2 (en) | 2018-01-03 | 2020-10-08 | Sapience Therapeutics, Inc. | ATF5 peptide variants and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| WO1999067288A1 (en) | 1998-06-25 | 1999-12-29 | Sumitomo Pharmaceuticals Company, Limited | Tumor antigen peptides originating in cyclophilin b |
| US20020103360A1 (en) | 1998-09-01 | 2002-08-01 | Yang Pan | Novel protein related to melanoma-inhibiting protein and uses thereof |
| US20030045491A1 (en) * | 2001-02-23 | 2003-03-06 | Christoph Reinhard | TTK in diagnosis and as a therapeutic target in cancer |
| EP1377596B1 (en) * | 2001-02-21 | 2012-04-11 | Novartis Vaccines and Diagnostics, Inc. | Ttk in diagnosis and as a therapeutic target in cancer |
| ES2401326T3 (es) | 2001-11-21 | 2013-04-18 | Astellas Pharma Inc. | Procedimiento para inhibir la expresión génica |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| EP1556402B1 (en) | 2002-09-25 | 2011-06-22 | University of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
| TW200413725A (en) | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Method for diagnosing non-small cell lung cancers |
| US20060024692A1 (en) * | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| DE602004015064D1 (de) * | 2003-01-06 | 2008-08-28 | Wyeth Corp | Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs |
| US20050266409A1 (en) * | 2003-02-04 | 2005-12-01 | Wyeth | Compositions and methods for diagnosing, preventing, and treating cancers |
| US20060241072A1 (en) | 2003-06-20 | 2006-10-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds for use in gene modulation |
| US20050136437A1 (en) | 2003-08-25 | 2005-06-23 | Nastech Pharmaceutical Company Inc. | Nanoparticles for delivery of nucleic acids and stable double-stranded RNA |
| WO2005045037A2 (en) | 2003-10-23 | 2005-05-19 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| HUE033977T2 (en) | 2004-08-23 | 2018-02-28 | Sylentis Sau | Treatment of eye disorders with siRNAs characterized by increased intraocular pressure |
| CN102747141A (zh) * | 2004-12-08 | 2012-10-24 | 安万特药物公司 | 测量对多西他赛抗药性或敏感性的方法 |
| JP5109131B2 (ja) * | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| PL2325306T3 (pl) * | 2005-02-25 | 2014-07-31 | Oncotherapy Science Inc | Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1 |
| CN101273144B (zh) * | 2005-07-27 | 2011-12-28 | 肿瘤疗法科学股份有限公司 | 诊断食道癌的方法 |
| TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2007
- 2007-12-12 WO PCT/JP2007/074359 patent/WO2008072777A2/en not_active Ceased
- 2007-12-12 EP EP11185101A patent/EP2468886A1/en not_active Withdrawn
- 2007-12-12 JP JP2009524832A patent/JP2010512730A/ja not_active Withdrawn
- 2007-12-12 EP EP07859848A patent/EP2102360A2/en not_active Withdrawn
- 2007-12-12 TW TW096147377A patent/TW200831673A/zh unknown
- 2007-12-12 US US12/518,876 patent/US20100009920A1/en not_active Abandoned
- 2007-12-12 EP EP11185104A patent/EP2468887A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010111120A (ru) | Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого | |
| EP2396342B1 (en) | Mutant ros expression in human liver cancer | |
| JP6619070B2 (ja) | 肺癌におけるｒｏｓキナーゼ | |
| DK2738255T3 (en) | ERAP1-Derived Peptide and its Use | |
| JP2010500003A5 (enExample) | ||
| Gao et al. | Multiple splice variants of Par3 and of a novel related gene, Par3L, produce proteins with different binding properties | |
| Gutmann et al. | Neurofibromatosis 2 tumor suppressor protein, merlin, forms two functionally important intramolecular associations | |
| JP2010511382A5 (enExample) | ||
| EP2898327A1 (en) | Dynamic bh3 profiling | |
| JP2010512730A (ja) | 肺癌の腫瘍マーカーおよび治療標的としてのｔｔｋ | |
| JP2012501165A5 (enExample) | ||
| JP2010523081A5 (enExample) | ||
| Wu et al. | Protein phosphatase type-1 and glycogen bind to a domain in the skeletal muscle regulatory subunit containing conserved hydrophobic sequence motifs | |
| JP5150855B2 (ja) | Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法 | |
| Yi et al. | Two variants of MutS homolog hMSH5: prevalence in humans and effects on protein interaction | |
| WO2008023841A1 (en) | Breast cancer-associated gene, melk, and its interactions with bcl-g | |
| CA2494577A1 (en) | Mk2 interacting proteins | |
| JP2009502732A5 (enExample) | ||
| CN108137660A (zh) | 用于纯化和定量凝溶胶蛋白及其变体的适体 | |
| EP1361285A2 (en) | Protein kinase peptide substrate determination using peptide libraries | |
| US9267119B2 (en) | Phosphatidylinositol phosphate kinase type 1 gamma splice variants as biomarkers and drug targets for epithelial cancers | |
| US20240425555A1 (en) | Mutant brd4 polypeptides and methods of use thereof | |
| US20230374088A1 (en) | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7 | |
| US20190269784A1 (en) | Selective Inhibitors of the Polo-Like Kinase 1 Polo-Box Domain | |
| JP2012506236A (ja) | 抗肺がん化合物または抗食道がん化合物のスクリーニング方法 |